Home LiteratureArticle Details
PMID: 14742182 Published · ppublish English Journal Article Review

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Antimicrobial agents and chemotherapy ·Vol. 48 ·No. 2 ·2004-02-00 ·Pages 369-77

Mueller M, de la Peña A, Derendorf H

Abstract

暂无摘要

MeSH Terms
Algorithms Anti-Infective Agents/pharmacokinetics,pharmacology Bacteria/drug effects Bacterial Infections/drug therapy,microbiology Dose-Response Relationship, Drug Humans Microbial Sensitivity Tests Models, Biological
Chemicals
Anti-Infective Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Mueller Markus
Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
de la Peña Amparo
Derendorf Hartmut
References (117)
117 references, click to expand
  1. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models.
    Antimicrob Agents Chemother. 1995 May;39(5):1054-8 PMID: 7625788
  2. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.
    Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89-96 PMID: 7587056
  3. Two compartment kinetic model with multiple artificial capillary units.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:131-7 PMID: 3980324
  4. An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:103-9 PMID: 3980320
  5. Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis.
    J Vet Pharmacol Ther. 1996 Apr;19(2):95-103 PMID: 8735415
  6. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
    DICP. 1991 Oct;25(10):1050-7 PMID: 1803788
  7. Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens.
    Drug Intell Clin Pharm. 1987 Feb;21(2):187-92 PMID: 3829911
  8. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.
    J Antimicrob Chemother. 1997 Apr;39(4):515-8 PMID: 9145825
  9. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA.
    Eur J Clin Microbiol Infect Dis. 1995 Jul;14(7):636-42 PMID: 7588857
  10. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.
    Antimicrob Agents Chemother. 1987 Jul;31(7):1054-60 PMID: 3116917
  11. Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.
    Curr Opin Infect Dis. 1998 Dec;11(6):673-80 PMID: 17035742
  12. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    J Antimicrob Chemother. 1999 Apr;43(4):483-90 PMID: 10350376
  13. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13 PMID: 9352388
  14. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.
    Clin Pharmacokinet. 1997 Aug;33(2):142-52 PMID: 9260036
  15. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.
    Clin Pharmacokinet. 1999 Oct;37(4):289-304 PMID: 10554046
  16. In vivo verification of in vitro model of antibiotic treatment of device-related infection.
    Antimicrob Agents Chemother. 1995 May;39(5):1134-9 PMID: 7625801
  17. An in vitro model of the urinary bladder.
    J Antimicrob Chemother. 1978 Mar;4(2):113-20 PMID: 348666
  18. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.
    J Antimicrob Chemother. 2000 Mar;45(3):321-8 PMID: 10702551
  19. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    J Chemother. 1999 Dec;11(6):426-39 PMID: 10678784
  20. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model.
    Antimicrob Agents Chemother. 1995 Aug;39(8):1764-71 PMID: 7486916
  21. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.
    Antimicrob Agents Chemother. 1998 Sep;42(9):2188-92 PMID: 9736533
  22. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins.
    J Infect Dis. 1986 Sep;154(3):511-7 PMID: 3734494
  23. An in vitro pharmacodynamic model to simulate antibiotic behavior of acute otitis media with effusion.
    Pharm Res. 1992 Jul;9(7):920-4 PMID: 1438006
  24. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms.
    J Exp Med. 1948 Jul;88(1):99-131 PMID: 18871882
  25. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.
    J Pharm Sci. 1971 Jun;60(6):892-5 PMID: 5166939
  26. Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model.
    Antimicrob Agents Chemother. 1997 Jan;41(1):7-12 PMID: 8980746
  27. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations.
    Int J Clin Pharmacol Ther. 1997 Oct;35(10):426-33 PMID: 9352391
  28. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Clin Pharmacokinet. 1995 Feb;28(2):143-60 PMID: 7736689
  29. Influence of protein binding on therapeutic efficacy of cefoperazone.
    Antimicrob Agents Chemother. 1989 Apr;33(4):566-8 PMID: 2729948
  30. Pharmacodynamics of antimicrobial therapy in surgery.
    Am J Surg. 1996 Jun;171(6):615-22 PMID: 8678212
  31. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.
    Scand J Infect Dis Suppl. 1989;58:1-55 PMID: 2499924
  32. Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyser: results of experiments with ciprofloxacin.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:159-67 PMID: 3156839
  33. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
    Pediatr Infect Dis J. 1996 Mar;15(3):255-9 PMID: 8852915
  34. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Antimicrob Agents Chemother. 1999 Mar;43(3):498-502 PMID: 10049257
  35. Time course of the pharmacological response to beta-lactam antibiotics in vitro and in vivo.
    Eur J Clin Microbiol. 1984 Dec;3(6):592-7 PMID: 6098475
  36. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.
    Antimicrob Agents Chemother. 1998 Mar;42(3):521-7 PMID: 9517926
  37. Pharmacokinetics of the oral cephalosporins in adults.
    J Int Med Res. 1980;8(Suppl 1):2-8 PMID: 7439500
  38. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics.
    Antimicrob Agents Chemother. 1980 Sep;18(3):377-81 PMID: 6999984
  39. An in vitro tissue culture bilayer model to examine early events in Mycobacterium tuberculosis infection.
    Infect Immun. 1999 Feb;67(2):653-8 PMID: 9916072
  40. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy.
    Crit Rev Ther Drug Carrier Syst. 1999;16(6):571-639 PMID: 10677802
  41. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.
    Infect Dis Clin North Am. 1999 Sep;13(3):595-618 PMID: 10470557
  42. Kinetics and mechanisms of drug action on microorganisms. XVII. Bactericidal effects of penicillin, kanamycin, and rifampin with and without organism pretreatment with bacteriostatic chloramphenicol, tetracycline, and novobiocin.
    J Pharm Sci. 1973 Oct;62(10):1666-73 PMID: 4584653
  43. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.
    Antimicrob Agents Chemother. 2000 May;44(5):1247-54 PMID: 10770759
  44. Kinetics and mechanisms of drug action on microorganisms. IX. Inhibitory action of lincomycin on Escherichia coli by microbial kinetics.
    Chemotherapy. 1969;14(6):337-55 PMID: 4904399
  45. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model.
    Antimicrob Agents Chemother. 1990 Jul;34(7):1312-7 PMID: 2117416
  46. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats.
    Antimicrob Agents Chemother. 1987 Feb;31(2):139-43 PMID: 3105445
  47. Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions.
    Infection. 1980;Suppl 1:103-8 PMID: 6995345
  48. Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells.
    Antimicrob Agents Chemother. 1991 Jan;35(1):68-72 PMID: 2014983
  49. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.
    Antimicrob Agents Chemother. 1996 Dec;40(12):2727-31 PMID: 9124830
  50. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
    Antimicrob Agents Chemother. 1998 Nov;42(11):2841-7 PMID: 9797213
  51. Correction for bacterial loss in in vitro dilution models.
    Antimicrob Agents Chemother. 1987 Nov;31(11):1859-60 PMID: 3324963
  52. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods.
    J Antimicrob Chemother. 1986 Mar;17 Suppl A:1-5 PMID: 3086275
  53. An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions.
    Infection. 1980;Suppl 1:096-10 PMID: 6772578
  54. Computer-controlled in-vitro simulation of multiple dosing regimens.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:169-73 PMID: 3920179
  55. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis.
    Clin Infect Dis. 1998 Jul;27(1):47-50 PMID: 9675448
  56. Antimicrobial resistance issues of the future.
    Diagn Microbiol Infect Dis. 1996 Aug;25(4):213-7 PMID: 8937847
  57. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
    Antimicrob Agents Chemother. 1992 Sep;36(9):1883-9 PMID: 1329634
  58. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
    Clin Pharmacokinet. 1999 Jul;37(1):1-16 PMID: 10451780
  59. Once-daily dosing of aminoglycosides.
    Eur J Clin Microbiol Infect Dis. 1995 Dec;14(12):1029-38 PMID: 8681976
  60. Long-standing otitis media with effusion--a convenient model for the study of antibiotic penetration to respiratory tract secretions.
    Scand J Infect Dis Suppl. 1985;44:46-51 PMID: 3860937
  61. Ten years of ciprofloxacin: the past, present and future. Antimicrobial susceptibility. Introduction.
    J Antimicrob Chemother. 1999 Mar;43 Suppl A:1-2 PMID: 10225566
  62. Use of an in-vitro kinetic model to study antibiotic combinations.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:221-6 PMID: 3920181
  63. The pharmacodynamics of beta-lactams.
    Clin Infect Dis. 1998 Jul;27(1):10-22 PMID: 9675443
  64. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.
    Pharm Res. 1999 Feb;16(2):176-85 PMID: 10100300
  65. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.
    Antimicrob Agents Chemother. 1990 Apr;34(4):510-4 PMID: 2140496
  66. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model.
    Antimicrob Agents Chemother. 1996 Nov;40(11):2478-82 PMID: 8913449
  67. Influence of aminopenicillins on bacterial growth kinetics in vitro in comparison with the antibacterial effect in vivo.
    Infection. 1979;7 Suppl 5:S434-7 PMID: 389820
  68. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
    Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2 PMID: 9455502
  69. Kinetics and mechanisms of action of antibiotics on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates.
    J Pharm Sci. 1966 Jun;55(6):593-600 PMID: 5332367
  70. Pharmacodynamic interactions of antibiotics alone and in combination.
    Clin Infect Dis. 1998 Jul;27(1):40-6 PMID: 9675447
  71. Beta-lactam antibiotics: is continuous infusion the preferred method of administration?
    Ann Pharmacother. 1995 Apr;29(4):415-24 PMID: 7633021
  72. Pharmacokinetic evaluation of beta-lactam antibiotics.
    J Antimicrob Chemother. 1989 Sep;24(3):407-13 PMID: 2681120
  73. An experimental model for the study of the antibacterial activity of the sulfonamides.
    Chemotherapy. 1968;13(1):54-60 PMID: 5656316
  74. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.
    J Antimicrob Chemother. 1991 May;27 Suppl C:29-40 PMID: 1830302
  75. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis.
    J Antimicrob Chemother. 1984 Dec;14(6):619-31 PMID: 6520062
  76. Effect of antibiotics eliminated by first order kinetics.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:147-52 PMID: 3980326
  77. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.
    J Infect Dis. 1988 Oct;158(4):831-47 PMID: 3139779
  78. Kinetics of antimicrobial action.
    Scand J Infect Dis Suppl. 1978;(14):54-85 PMID: 30169
  79. Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice.
    J Antimicrob Chemother. 1985 Nov;16(5):605-13 PMID: 3935638
  80. Effects of sub-bactericidal concentrations of antibiotics in experimental models of endocarditis.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:293-6 PMID: 3884570
  81. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.
    Antimicrob Agents Chemother. 1978 Apr;13(4):570-6 PMID: 352258
  82. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.
    Scand J Infect Dis Suppl. 1990;74:235-48 PMID: 2097712
  83. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens.
    Antimicrob Agents Chemother. 1988 Dec;32(12):1825-9 PMID: 3245695
  84. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.
    J Infect Dis. 1987 Jan;155(1):93-9 PMID: 3540140
  85. Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. II. Description of experiments.
    Chemotherapy. 1986;32(1):44-58 PMID: 3512195
  86. Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro.
    Pharm Res. 1996 Jan;13(1):91-6 PMID: 8668686
  87. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers.
    Clin Pharmacol Ther. 2000 Mar;67(3):229-36 PMID: 10741625
  88. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance.
    Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S18-21 PMID: 10654631
  89. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    Antimicrob Agents Chemother. 1985 Jul;28(1):64-8 PMID: 3929682
  90. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
    Antimicrob Agents Chemother. 1994 Sep;38(9):2034-40 PMID: 7811015
  91. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.
    J Infect Dis. 1989 Feb;159(2):281-92 PMID: 2644371
  92. Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing.
    Clin Infect Dis. 1998 Aug;27 Suppl 1:S111-6 PMID: 9710679
  93. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria.
    J Infect Dis. 1994 Sep;170(3):720-3 PMID: 7915751
  94. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus.
    J Infect Dis. 1990 Sep;162(3):705-10 PMID: 2387996
  95. [Inhibition of biofilm formation by clarithromycin (CAM) in an experimental model of complicated bladder infection--in vitro study using automated simulation of urinary antimicrobial concentration].
    Kansenshogaku Zasshi. 1994 Nov;68(11):1306-17 PMID: 7829898
  96. AUIC--a general target for the optimization of dosing regimens of antibiotics?
    Ann Pharmacother. 1996 Sep;30(9):1024-8 PMID: 8876867
  97. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.
    Antimicrob Agents Chemother. 1987 Jun;31(6):895-8 PMID: 3619421
  98. Successful prophylaxis of experimental streptococcal endocarditis with single doses of sublethal concentrations of penicillin.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:297-302 PMID: 3980332
  99. Kinetics and mechanisms of drug action on microorganisms. XIV. The action of fluorouracil, other uracils and derived nucleosides on the microbial kinetics of Escherichia coli.
    Chemotherapy. 1972;17(2):81-108 PMID: 4558401
  100. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
    J Antimicrob Chemother. 2000 Mar;45:9-17 PMID: 10719007
  101. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
    Antimicrob Agents Chemother. 1994 Dec;38(12):2730-7 PMID: 7695254
  102. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
    Antimicrob Agents Chemother. 1997 Jun;41(6):1281-7 PMID: 9174184
  103. Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. I. Description of the model.
    Chemotherapy. 1986;32(1):37-43 PMID: 3081303
  104. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
    Antimicrob Agents Chemother. 1998 Mar;42(3):659-65 PMID: 9517948
  105. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa.
    J Pharmacokinet Biopharm. 1988 Aug;16(4):355-75 PMID: 3193364
  106. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.
    Antimicrob Agents Chemother. 1994 May;38(5):1112-7 PMID: 8067747
  107. Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model.
    Antimicrob Agents Chemother. 1998 Jul;42(7):1731-7 PMID: 9661013
  108. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients.
    Am J Health Syst Pharm. 1999 Nov 15;56(22 Suppl 3):S21-4 PMID: 10580737
  109. Kinetics of antimicrobial action.
    Rev Infect Dis. 1981 Jan-Feb;3(1):19-27 PMID: 7221359
  110. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration.
    J Infect Dis. 1982 Feb;145(2):160-8 PMID: 7033400
  111. New approach to the evaluation of antibacterial activity of aminosidine.
    Chemotherapy. 1973;18(5):297-303 PMID: 4580525
  112. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:313-21 PMID: 3980334
  113. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.
    Antimicrob Agents Chemother. 1985 Mar;27(3):343-9 PMID: 3922294
  114. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis.
    Antimicrob Agents Chemother. 1998 Oct;42(10):2739-44 PMID: 9756787
  115. Choosing an antibiotic on the basis of pharmacodynamics.
    Ear Nose Throat J. 1998 Jun;77(6 Suppl):7-11; discussion 11-2 PMID: 9674328
  116. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
    Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S9-11 PMID: 10654629
  117. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.
    Antimicrob Agents Chemother. 1999 Sep;43(9):2268-72 PMID: 10471577
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
DOI
10.1128/AAC.48.2.369-377.2004
Published
2004-02-00
Pages
369-77
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC321563
Subset
IM
External Links
PubMed source DOI: 10.1128/AAC.48.2.369-377.2004 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2